The U.S. Food and Drug Administration recently approved a higher dose Exelon Patch (rivastigmine transdermal system) for people with mild to moderate Alzheimer’s disease. The new 13.3 mg/24 h dosage strength of the Exelon Patch provides physicians with a new treatment option for patients who are experiencing a decline in overall function and cognition. Patients treated with the higher-dose patch experienced statistically significant improvement in their overall function, as well as cognitive functioning, researchers said.
